Abstract Numerous systemic infections may have hypercoagulation as one of the complications, which range from asymptomatic presentation elevation biochemical markers coagulation such that fibrin and thrombin generation, to a much severe, symptomatic, life-threatening, disseminated intravascular (DIC), results in formation thrombi microvasculature various organs. This phenomenon contributes incr...

BACKGROUND The resistance of thrombi to fibrinolysis induced by plasminogen activators remains a major impediment to the successful treatment of thrombotic diseases. This study examines the contribution of activated factor XIII (factor XIIIa) to fibrinolytic resistance in experimental pulmonary embolism. METHODS AND RESULTS The fibrinolytic effects of specific inhibitors of factor XIIIa-media...

Blood clots and thrombi consist primarily of a mesh of branched fibers made of the protein fibrin. We propose a molecular basis for the marked extensibility and negative compressibility of fibrin gels based on the structural and mechanical properties of clots at the network, fiber, and molecular levels. The force required to stretch a clot initially rises linearly and is accompanied by a dramat...

Activation of plasminogen by agents such as tissue-type plasminogen activator (tPA), yields plasmin, lyses fibrin, and thereby restores flow to blood vessels occluded by thrombi. Because tPA binds to fibrin, as does plasminogen, at low doses, tPA-mediated generation of plasmin is localized, rendering tPA clot selective. This result, plus its short half-life (4.5 minutes), led to the hope that i...

Thrombus extension in patients with venous thromboembolism is due to the accretion of fibrin onto existing thrombi. Extension is promoted by both circulating and thrombus-bound thrombin, which convert fibrinogen to fibrin. Heparin is an effective antithrombotic agent, but it requires continuous administration to achieve persistent inhibition of thrombus extension. Heparin is highly effective in...

ross-sections, additional special factors, such as discontinuation of ntiplatelet therapy, antiplatelet resistance, intrinsic thrombogeicity, or coronary flow problems might trigger the development f LST. In comparison with previous data of 3-month follow-up (paients n 21, struts n 4,545) (3), thickness of NIH in the 2-year ollow-up group was greater than that in the 3-month follow-up roup (71 ...

Sibutramine is used in the treatment of obesity due to its ability to influence feelings of hunger and satiety by inhibiting the re-uptake of serotonin and noradrenalin in the central nervous system (CNS). Sibutramine use has been associated with numerous adverse events in particular cardiovascular complications possibly due to the formation of thrombi. This ultrastructural descriptive study in...

Mechanisms underlying airway hyperresponsiveness are not yet fully elucidated. One of the manifestations of airway inflammation is leakage of diverse plasma proteins into the airway lumen. They include fibrinogen and thrombin. Thrombin cleaves fibrinogen to form fibrin, a major component of thrombi. Fibrin inactivates surfactant. Surfactant on the airway surface maintains airway patency by lowe...

Abciximab (c7E3 Fab, ReoPro), a platelet glycoprotein (GP) IIb/IIIa inhibitor, decreases acute ischemic complications after percutaneous coronary interventions. Recently, abciximab was shown to decrease thrombin generation in vitro in a static system. To assess whether abciximab can decrease fibrin formation in blood from patients, we quantified both platelet thrombi and fibrin deposition by us...

Exposure of type III collagen coats on plastic cover slips in parallel-plate perfusion chambers to flowing nonanticoagulated human blood resulted in deposition of platelets and fibrin. Blood was drawn directly from an antecubital vein by an occlusive roller pump over the collagen coats in chambers having flow slits of different dimensions, so that wall shear rates of 100, 650, and 2600 s-1 were...